133 related articles for article (PubMed ID: 29843049)
1. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis.
Salah S; Lewin J; Amir E; Abdul Razak A
Cancer Treat Rev; 2018 Sep; 69():1-10. PubMed ID: 29843049
[TBL] [Abstract][Full Text] [Related]
2. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative.
Zaidi MY; Ethun CG; Tran TB; Poultsides G; Grignol VP; Howard JH; Bedi M; Mogal H; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick B; Fields RC; Oskouei S; Reimer N; Monson D; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Oct; 26(11):3542-3549. PubMed ID: 31342400
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas.
Grabellus F; Podleska LE; Sheu SY; Bauer S; Pöttgen C; Kloeters C; Hoiczyk M; Lauenstein TC; Schmid KW; Taeger G
Eur J Surg Oncol; 2013 Jan; 39(1):61-7. PubMed ID: 23103117
[TBL] [Abstract][Full Text] [Related]
5. The Effect of chemo- and radiotherapy on tumor necrosis in soft tissue sarcoma- does it influence prognosis?
Fromm J; Klein A; Kirilova M; Lindner LH; Nachbichler S; Holzapfel BM; Goller SS; Knösel T; Dürr HR
BMC Cancer; 2024 Mar; 24(1):303. PubMed ID: 38448852
[TBL] [Abstract][Full Text] [Related]
6. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
Eilber FC; Rosen G; Eckardt J; Forscher C; Nelson SD; Selch M; Dorey F; Eilber FR
J Clin Oncol; 2001 Jul; 19(13):3203-9. PubMed ID: 11432887
[TBL] [Abstract][Full Text] [Related]
7. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Pasquali S; Colombo C; Pizzamiglio S; Verderio P; Callegaro D; Stacchiotti S; Martin Broto J; Lopez-Pousa A; Ferrari S; Poveda A; De Paoli A; Quagliuolo V; Jurado JC; Comandone A; Grignani G; De Sanctis R; Palassini E; Llomboart-Bosch A; Dei Tos AP; Casali PG; Picci P; Gronchi A
Eur J Cancer; 2018 Apr; 93():28-36. PubMed ID: 29475197
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma.
Menendez LR; Ahlmann ER; Savage K; Cluck M; Fedenko AN
Clin Orthop Relat Res; 2007 Feb; 455():219-24. PubMed ID: 17016226
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma.
Vaynrub M; Taheri N; Ahlmann ER; Yao C; Fedenko AN; Allison DC; Chawla SP; Menendez LR
J Surg Oncol; 2015 Feb; 111(2):152-7. PubMed ID: 25175933
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity.
Sabolch A; Feng M; Griffith K; Rzasa C; Gadzala L; Feng F; Biermann JS; Chugh R; Ray M; Ben-Josef E
Am J Clin Oncol; 2012 Apr; 35(2):151-7. PubMed ID: 21336091
[TBL] [Abstract][Full Text] [Related]
11. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
13. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
15. Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.
Zer A; Prince RM; Amir E; Abdul Razak AR
Cancer Treat Rev; 2018 Feb; 63():71-78. PubMed ID: 29253836
[TBL] [Abstract][Full Text] [Related]
16. Histologic Response to Neoadjuvant Therapy Is Not Predictive of Favorable Outcomes in High-grade Pleomorphic Soft Tissue Sarcoma.
Cates JMM
Am J Surg Pathol; 2019 Apr; 43(4):564-572. PubMed ID: 30628925
[TBL] [Abstract][Full Text] [Related]
17. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
Lucas DR; Kshirsagar MP; Biermann JS; Hamre MR; Thomas DG; Schuetze SM; Baker LH
Oncologist; 2008 Apr; 13(4):451-8. PubMed ID: 18448561
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion: what is the evidence for its use?
Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BB
Ann Surg Oncol; 2004 Sep; 11(9):837-45. PubMed ID: 15313738
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
20. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
